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Backgorund: Concurrent iliac occlusion and abdominal aortic aneu-
rysm is rare. Traditionally, the endovascular approach to these patients has
consisted of aorto-uni-iliac devices combined with femoral-femoral bypass.
This approach may hinder future endovascular interventions and potentially
increase the risk of groin infections. With improved facility of subintimal
angioplasty techniques, standard bifurcated endografts represent an alterna-
tive option in these patients. The purpose of this study was to examine
outcomes of patients undergoing iliac recanalization and traditional bifur-
cated EVAR in the face of access vessel occlusion.
Methods: A retrospective review of patients at three academic tertiary-
referral centers who underwent attempted iliac recanalization of chronic iliac
occlusions and concurrent endovascular repair of an infrarenal aortic aneu-
rysm was performed. Patients with acute iliac thrombosis, as well as those
with severely stenotic (but patent) iliac vessels were excluded.
Results:Over a 6-year period, 15 occluded iliac arteries were treated in
fourteen patients. Mean age was 67.8 years (range 52-80) and male:female
ratio was 13:1. Primary indication for intervention was disabling claudica-
tion in 4 patients and size of AAA in 10 patients. Seven patients presented
with a unilateral common iliac artery (CIA) occlusion, 4 with a unilateral
external iliac artery (EIA) occlusion, 3 with a unilateral combined CIA and
EIA occlusion, and one with bilateral CIA occlusions. Two of the occluded
CIAs and one of the occluded EIAs had prior stents. Average length of the
occluded segment was 7.5 cm (Range 2-17). The mean diameter of the
occluded CIAs and EIAs were 8.6 and 5.7 mm, respectively. Successful
recanalization was achieved in 14 of the 15 vessels (93.3%). One EIA
ruptured during recanalization, but was easily controlled with a Viabahn
stent. A re-entry device was used in two cases. Overall, 13 bifurcated devices
were implanted: 8 Gore Excluder, 4 Cook Zenith, and 1 Medtronic Talent.
The lone technical failure was in the patient with an occluded EIA stent, who
was treated with a Cook Renu graft and adjuvant femoral-femoral bypass.
The mean length of stay was 2.3 days (range 1-6). There were no major
peri-operative complications or mortality. During a mean follow-up of 28.2
months (range 1-86months) there was 100% primary patency of successfully
recanalized iliacs. Aneurysm sac size decreased from amean of 5.1 cm (range
3.1-7.6) preop to 4.4 cm (range 2.8-7.1) at follow-up. No aneurysms grew
or ruptured. There were 3 endoleaks (all Type II), one of which required
coiling at 15 months. There were two late deaths: one at 36 months
secondary to complications from aCABG/MVR and one at 34months from
a myocardial infarction.
Conclusions: The use of bifurcated endovascular devices following
recanalization of an occluded iliac system is both technically feasible and
durable at midterm follow-up. This technique reestablishes aortoiliac inflow
to both extremities, obviates the need for extra-anatomic bypass, and may
preserve hypogastric perfusion in some patients. Prior stent placement in the
occluded access vessel may increase the risk of technical failure.
Mortality in Patients with Premature Lower Extremity Atherosclerosis
Hamza Rana, Jeanette Stafford Andrews, Billy Chacko, Kimberley J. Hansen,
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Introduction: Lower extremity peripheral artery disease which occurs
mostly in elderly is associated with high mortality. No data are available
regarding long term mortality in patients with premature lower extremity
atherosclerosis (PLEA). Our objective was to determine the all cause mor-
tality and its predictors in younger PLEA patients.
Methods: We studied patients with severe PLEA 55 years of age at
diagnosis treated at single academic vascular center between 1998 and 2010.
Data were collected prospectively at the initial evaluation for vascular care.
National Death Index (NDI) and hospital records were used to determine all
cause mortality. Demographic and clinical characteristics were summarized
using count (%) or mean  SD. Survival times were estimated using
Kaplan-Meier estimates, and associations with covariates were tested using
simple and multivariable Cox proportional hazards models.
Results: Total of 564 patients were analyzed (46% female; 20% Black,
with mean age 49.38  6.44 yrs). Ninty five percent of patients have  2
cardiovascular risk factors; 31% had coronary artery disease (CAD), and 10%
had history of cancer. During a median follow-up of 5.6 years (IQR, 2.3-8.4
yrs), 108 (19%) deaths were recorded. 2- year estimated mortality was 6%
and 5- year estimated mortality was 16%. In univariate regression analysis,atient age (P  .04), prior amputation (P  .01), history of cancer (P 
02) and established CAD (P  .03) were associated with increased risk of
ortality. Aspirin use and lipid lowering therapy (LLT) at the time of first
valuation were associated with improved survival (P  .01 and P  .01
espectively). The Fig shows Kaplan-Meier estimates stratified according to
istory of aspirin use and cancer status. A multivariable Cox proportional
azard model identified age (HR for 5-year increase 1.2; 95% CI 1.0-1.4; P
.04), prior amputation (HR 2.0; 95% CI 1.2-3.3; P  .01), history of
ancer (HR 2.4; 95%CI 1.4-4.1; P .01), CAD (HR1.8; 95%CI 1.2-2.7; P
.01) as independent predictors of mortality in patients with PLEA.
mportantly, history of aspirin use had significant protective effect (HR 0.4;
5%CI 0.3-0.7; P  .01). The impact of LLT was no longer significant in
ultivariable model.
Conclusions: Patients with PLEA demonstrate a high follow-up mor-
ality. No traditional cardiovascular risk factors predicted mortality. Aspirin
herapy at the time of first evaluation was a significant and independent
redictor of improved survival in patients with PLEA.Fig.
